Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$12.12 CAD
Change Today +0.25 / 2.11%
Volume 800.0
COM On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 10:49 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Open
C$12.30
Previous Close
C$11.87
Day High
C$12.30
Day Low
C$12.12
52 Week High
01/21/15 - C$13.80
52 Week Low
09/4/14 - C$7.12
Market Cap
233.7M
Average Volume 10 Days
2.9K
EPS TTM
C$-1.31
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$650.0K
Chief Financial Officer
Total Annual Compensation: C$275.0K
Chief Operating Officer
Total Annual Compensation: C$240.0K
Corporate General Counsel
Total Annual Compensation: C$248.5K
Compensation as of Fiscal Year 2014.

cardiome pharma corp (COM) Key Developments

United Kingdom Department of Health Sets Pricing of BRINAVESS of Cardiome Pharma Corporation

Cardiome Pharma Corp. announced that the Secretary of State for the U.K. Department of Health has approved pricing for BRINAVESS (vernakalant hydrochloride). The approved amount represents a maximum price per vial of BRINAVESS in the United Kingdom. It is consistent with pricing in other territories and Cardiome's economic forecasts.

Cardiome Pharma Corp. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Cardiome Pharma Corp. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. The company recorded a net loss of $7.4 million or basic and diluted loss per share of $0.43 for the three months ended June 30, 2015, compared to a net loss of $4.2 million or basic and diluted loss per share of $0.26 for the three months ended June 30, 2014. The increase in the net loss during the second quarter of 2015 was largely due to a $3.0 million payment to SteadyMed Ltd. upon execution of an exclusive license and supply agreement for the commercialization of TREVYENT in Europe, Canada and the Middle East. Revenue for the three months ended June 30, 2015 was $5.7 million, compared to revenue of $7.7 million for the three months ended June 30, 2014. Operating loss was $7.425 million against $4.007 million a year ago. Net loss before income taxes was $7.288 million against $4.084 million a year ago. Net cash used in operating activities was $4.615 million against $3.328 million a year ago. Purchase of property and equipment was $43,000 against $14,000 a year ago. On a year-to-date basis, the company recorded a net loss of $11.2 million or basic and diluted loss per share of $0.66 for the six months ended June 30, 2015, compared to a net loss of $7.4 million or basic and diluted loss per share of $0.46 for the six months ended June 30, 2014. Revenue for the six months ended June 30, 2015 and 2014 was $11.2 million and $15.3 million, respectively. The decreases in each period were due primarily to the timing of distributor sales, a decrease in AGGRASTAT sales due to generic competition and foreign exchange translation on Euro denominated revenue. Operating loss was $10.082 million against $6.688 million a year ago. Net loss before income taxes was $11.068 million against $7.101 million a year ago. Net cash used in operating activities was $7.755 million against $12.624 million a year ago. Purchase of property and equipment was $133,000 against $17,000 a year ago.

Cardiome Pharma Corp., Q2 2015 Earnings Call, Aug 05, 2015

Cardiome Pharma Corp., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$12.12 CAD +0.25

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $80.60 USD +0.80
Medicure Inc C$2.77 CAD -0.07
Merck & Co Inc $52.53 USD -0.005
Medicines Co/The $40.17 USD -0.80
View Industry Companies
 

Industry Analysis

COM

Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 14.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.